As CTLA4 administration was found to have a protective function both in prospective preclinical and retrospective human studies, we next sought to assess in depth the changes induced in the local and systemic cytokine milieu upon the anti-CTLA4 treatment in the lymphedema mouse tail model. The gene discussed is CTLA4; the disease is lymphedema.